Heidelberg Pharma AG/€HPHA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Heidelberg Pharma AG
Heidelberg Pharma AG is a biotechnology company focused on developing novel cancer therapies. It specializes in a proprietary technology known as Antibody Targeted Amanitin Conjugates (ATACs), aimed at delivering potent toxins specifically to cancer cells. Founded in Germany, the company is headquartered in Ladenburg and operates primarily in the pharmaceutical sector, with a strong emphasis on research and development collaborations. Heidelberg Pharma positions itself by leveraging its unique ATAC platform, differentiating itself through targeted cancer treatment modalities. The company collaborates with pharmaceutical firms to enhance its development pipeline and commercial reach across various markets. Sources:
https://www.heidelberg-pharma.com/
- Ticker
- €HPHA
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 33
- Headquarters
- Ladenburg, Germany
- Website
- heidelberg-pharma.com
HPHA Metrics
BasicAdvanced
€99M
-
-€0.66
0.78
-
Price and volume
Market cap
€99M
Beta
0.78
52-week high
€3.40
52-week low
€1.91
Average daily volume
3.9K
Financial strength
Current ratio
4.237
Quick ratio
2.958
Long term debt to equity
-0.008
Total debt to equity
-0.015
Interest coverage (TTM)
-3,654.29%
Profitability
EBITDA (TTM)
-32.57
Gross margin (TTM)
78.98%
Net profit margin (TTM)
-320.91%
Operating margin (TTM)
-352.32%
Effective tax rate (TTM)
-5.19%
Revenue per employee (TTM)
€280,000
Management effectiveness
Return on assets (TTM)
-42.36%
Return on equity (TTM)
680.19%
Valuation
Price to revenue (TTM)
10.303
Price to book
-4.76
Price to tangible book (TTM)
-3.27
Price to free cash flow (TTM)
-5.023
Free cash flow yield (TTM)
-19.91%
Free cash flow per share (TTM)
-0.417
Growth
Revenue change (TTM)
206.78%
Earnings per share change (TTM)
17.53%
3-year revenue growth (CAGR)
-0.48%
10-year revenue growth (CAGR)
16.10%
3-year earnings per share growth (CAGR)
11.21%
10-year earnings per share growth (CAGR)
0.24%
What the Analysts think about HPHA
Analyst ratings (Buy, Hold, Sell) for Heidelberg Pharma AG stock.
Analyst projections of the future price of Heidelberg Pharma AG stock.
HPHA Financial Performance
Revenues and expenses
HPHA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.